Drug intelligence / Profile preview

celecoxib + buprenorphine + tizanidine

Development stage
Phase 1
Lead developer
Second Affiliated Hospital of Zhejiang University School of Medicine
Modality
Small Molecules
Administration
Oral, Transdermal
01

Overview

This combination therapy is a multimodal analgesic regimen being investigated by the Second Affiliated Hospital, School of Medicine, Zhejiang University, for the management of postoperative pain and functional recovery in patients following shoulder arthroscopy for rotator cuff tears. The regimen consists of celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor; buprenorphine, a partial mu-opioid receptor agonist administered via a transdermal patch; and tizanidine, a centrally acting alpha-2 adrenergic agonist used as a skeletal muscle relaxant. By targeting multiple pain pathways—peripheral inflammation, central opioid signaling, and muscle spasticity—the combination aims to provide superior pain relief and improve joint function compared to standard dual-therapy regimens.

02

Targets

ADRA2A (α2A)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)NOP (Nociceptin/orphanin FQ peptide receptor)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on celecoxib + buprenorphine + tizanidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on celecoxib + buprenorphine + tizanidine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call